VICORE PHARMA
Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal.
VICORE PHARMA
Social Links:
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2009-01-01
Address:
Mölndal, Vastra Gotaland, Sweden
Country:
Sweden
Website Url:
http://www.vicorepharma.com
Total Employee:
11+
Status:
Active
Contact:
+46 (0) 31 788 05 60
Total Funding:
47.68 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress Google Analytics Content Delivery Network Global Site Tag
Similar Organizations
Cytokinetics
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Faron Pharmaceuticals
Faron Pharmaceuticals is a biopharmaceutical company engaged in the biotechnology and medical research industry.
Innovent Biologics
Innovent Biologics is a biopharmaceutical company that develops and manufactures monoclonal antibodies.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Sirnaomics
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.
Current Advisors List
Current Employees Featured
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2018-08-20 | INIM Pharma AB | INIM Pharma AB acquired by Vicore Pharma | N/A |
Investors List
Third Swedish National Pension Fund
Third Swedish National Pension Fund investment in Post-IPO Equity - Vicore Pharma
HealthCap
HealthCap investment in Post-IPO Equity - Vicore Pharma
HBM Healthcare Investments
HBM Healthcare Investments investment in Post-IPO Equity - Vicore Pharma
OrbiMed
OrbiMed investment in Post-IPO Equity - Vicore Pharma
Fjarde AP-fonden
Fjarde AP-fonden investment in Post-IPO Equity - Vicore Pharma
SEB (Skandinaviska Enskilda Banken)
SEB (Skandinaviska Enskilda Banken) investment in Post-IPO Equity - Vicore Pharma
Suvretta Capital Management
Suvretta Capital Management investment in Post-IPO Equity - Vicore Pharma
Swedbank Robur
Swedbank Robur investment in Post-IPO Equity - Vicore Pharma
LifeArc
LifeArc investment in Grant - Vicore Pharma
Official Site Inspections
http://www.vicorepharma.com Semrush global rank: 3.76 M Semrush visits lastest month: 3.16 K
- Host name: premium13.oderland.com
- IP address: 91.201.60.70
- Location: Sweden
- Latitude: 59.3247
- Longitude: 18.056
- Timezone: Europe/Stockholm
More informations about "Vicore Pharma"
Organization - Vicore Pharma
Our ambition and strategic prioritiesSee details»
Home - Vicore Pharma
Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is establishing a portfolio in respiratory diseases, including idiopathic …See details»
Management team - Vicore Pharma
Ã…sa has more than 20 years of experience as a commercial executive in the pharmaceutical industry with focus on securing market access and launching rare disease medicines.See details»
Vicore Pharma - Crunchbase Company Profile & Funding
Where is Vicore Pharma's headquarters? Vicore Pharma is located in Mölndal, Vastra Gotaland, Sweden. Who invested in Vicore Pharma? Vicore Pharma has 10 investors including Sanofi …See details»
Vicore Pharma Holding AB (publ) (VICO.ST) - Yahoo Finance
See the company profile for Vicore Pharma Holding AB (publ) (VICO.ST) including business summary, industry/sector information, number of employees, business summary, corporate …See details»
Vicore Pharma AB - LinkedIn
Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is establishing a portfolio in...See details»
Vicore Pharma AB | LinkedIn
Vicore is an innovative Swedish clinical-stage pharmaceutical company unlocking the potential of a new class of drugs to stop disease progression and restore function. The company is …See details»
Vicore Pharma Holding - Overview, News & Similar companies
Jan 3, 2024 · Vicore is a clinical-stage pharmaceutical company focused on developing innovative medicines in severe diseases where the Angiotensin II type 2 rec eptor (AT2R) plays an …See details»
Meet the Team - Vicore Pharma
Vicore is an agile organization with a highly experienced team throughout the entire value chain. Meet some of our colleagues here.See details»
Vicore Pharma Holding Company Profile | Management and
Vicore is a clinical-stage pharmaceutical company focused on developing innovative medicines in severe diseases where the Angiotensin II type 2 receptor (AT2R) plays an important role. The …See details»
Vicore Pharma Holding AB Company Description - Stock Analysis
Nov 21, 2024 · Company profile for Vicore Pharma Holding AB (publ) (STO: VICO) with a description, list of executives, contact details and other key facts.See details»
Vicore Pharma Holding - PitchBook
Nov 2, 2020 · Vicore Pharma Holding AB is as a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, …See details»
Vicore Pharma - Company Profile - Tracxn
Nov 15, 2024 · Vicore Pharma is a drug-development company focused on research on the AT2 receptor. The company's portfolio contains small molecules with potential indications including …See details»
VICORE PHARMA
Vicore will receive an upfront payment of USD 10 million and is eligible for up to USD 275 million in milestones, plus tiered royalties on net sales in Japan up to the low 20s. The partnership …See details»
Vicore Pharma publishes the Annual Report for 2020
GOTHENBURG, Sweden, April 15, 2021 /PRNewswire/ -- Vicore Pharma Holding AB (publ), a pharmaceutical company developing innovative medicines for severe lung disorders such as …See details»
Vicore Pharma - Craft
Sep 20, 2024 · Vicore is a rare disease company specializing in fibrotic lung disease and related indications. It has two drug development programs, VP01 and VP02. VP01 aims to develop …See details»
Vicore takes major step towards a clinical platform company …
Feb 23, 2022 · Building on its specific expertise Vicore announces that the first candidate in the VP03 program has completed preclinical development and is ready to enter the clinical …See details»
Overview - Vicore Pharma
Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is establishing a portfolio in …See details»
Vicore Pharma Holding AB (VICO) Stock Price & News - Google
Get the latest Vicore Pharma Holding AB (VICO) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.See details»
Our story - Vicore Pharma
Vicore is an innovative Swedish clinical-stage pharmaceutical company dedicated to creating life-changing treatments in diseases where the Angiotensin II Type 2 Receptor (AT2R) has a …See details»